Sutro Biopharma (STRO) Other Non-Current Assets (2017 - 2025)
Sutro Biopharma (STRO) reported Other Non-Current Assets of $858000.0 for Q4 2025, down 4.67% on a YoY basis from $900000.0 in Q4 2024, and little changed sequentially from $858000.0 in Q2 2025.
Sutro Biopharma (STRO) Other Non-Current Assets (2017 - 2025) Analysis & Trends
Sutro Biopharma (STRO) has 9 years of Other Non-Current Assets data on file, last reported at $858000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Assets fell 4.67% year-over-year to $858000.0; the trailing twelve-month figure through Dec 2025 stood at $858000.0 (down 4.67% YoY), and the FY2025 full-year result was $858000.0, down 4.67% from the prior year.
- Other Non-Current Assets held at $858000.0 in Q4 2025, from $858000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $900000.0 in Q4 2024 to a low of $857000.0 in Q1 2024.
- A 5-year average of $868894.7 and a median of $872000.0 in 2021 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets jumped 5713.33% in 2021 and retreated 4.67% in 2025, its largest moves.
- Tracing STRO's Other Non-Current Assets over 5 years: stood at $872000.0 in 2021, then changed by 0.0% to $872000.0 in 2022, then changed by 0.0% to $872000.0 in 2023, then grew by 3.21% to $900000.0 in 2024, then dropped by 4.67% to $858000.0 in 2025.
- Business Quant data shows STRO's Other Non-Current Assets at $858000.0 in Q4 2025, $858000.0 in Q2 2025, and $858000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Sutro Biopharma | 202.59 Mn | 61.16 Mn | - | 858,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 858,000.00 |
| Jun 30, 2025 | 858,000.00 |
| Mar 31, 2025 | 858,000.00 |
| Dec 31, 2024 | 900,000.00 |
| Sep 30, 2024 | 857,000.00 |
| Jun 30, 2024 | 857,000.00 |
| Mar 31, 2024 | 857,000.00 |
| Dec 31, 2023 | 872,000.00 |
| Sep 30, 2023 | 872,000.00 |
| Jun 30, 2023 | 872,000.00 |
| Mar 31, 2023 | 872,000.00 |
| Dec 31, 2022 | 872,000.00 |
| Sep 30, 2022 | 872,000.00 |
| Jun 30, 2022 | 872,000.00 |
| Mar 31, 2022 | 872,000.00 |
| Dec 31, 2021 | 872,000.00 |
| Sep 30, 2021 | 872,000.00 |
| Jun 30, 2021 | 872,000.00 |
| Mar 31, 2021 | 872,000.00 |
| Dec 31, 2020 | 872,000.00 |